[144] Insmed, Inc. SEC Filing
Insmed, Inc. insider filing on Form 144 notifies a proposed sale of 10,000 common shares through Merrill Lynch on Nasdaq, with an aggregate market value of $1,273,070. The filing lists the acquisition dates and amounts for 9 separate tranches received under the company stock plan between January 2022 and May 2023, totaling 8,820 shares disclosed in the acquisition table. The filer also reported recent open-market sales over the past three months: 99,172 shares on 06/11/2025, 38,300 shares on 06/10/2025, 1,642 on 06/03/2025, and 1,236 on 05/14/2025, producing gross proceeds of $12,853,585. The filer certifies no undisclosed material adverse information.
La comunicazione Insider di Insmed, Inc. su Form 144 segnala una proposta di vendita di 10.000 azioni ordinarie tramite Merrill Lynch sul Nasdaq, per un valore di mercato complessivo di $1.273.070. La dichiarazione indica le date e le quantit脿 di acquisizione per 9 tranche distinte ricevute nell鈥檃mbito del piano azionario aziendale tra gennaio 2022 e maggio 2023, per un totale di 8.820 azioni riportate nella tabella delle acquisizioni. Il dichiarante ha inoltre comunicato vendite recenti sul mercato aperto negli ultimi tre mesi: 99.172 azioni il 11/06/2025, 38.300 azioni il 10/06/2025, 1.642 il 03/06/2025 e 1.236 il 14/05/2025, con proventi lordi di $12.853.585. Il dichiarante certifica l鈥檃ssenza di informazioni materiali negative non divulgate.
La presentaci贸n de insider de Insmed, Inc. en el Formulario 144 notifica una propuesta de venta de 10.000 acciones ordinarias a trav茅s de Merrill Lynch en Nasdaq, con un valor de mercado agregado de $1.273.070. La notificaci贸n detalla las fechas y cantidades de adquisici贸n de 9 tramos distintos recibidos bajo el plan de acciones de la compa帽铆a entre enero de 2022 y mayo de 2023, sumando 8.820 acciones en la tabla de adquisiciones. El declarante tambi茅n inform贸 ventas recientes en mercado abierto durante los 煤ltimos tres meses: 99.172 acciones el 11/06/2025, 38.300 el 10/06/2025, 1.642 el 03/06/2025 y 1.236 el 14/05/2025, generando unos ingresos brutos de $12.853.585. El declarante certifica que no hay informaci贸n adversa material no divulgada.
Insmed, Inc.鞚� 雮措秬鞛� 鞁犼碃靹�(Form 144)電� Merrill Lynch毳� 韱淀暣 雮橃姢雼レ棎靹� 10,000 氤错喌欤� 毵り皝鞚� 鞝滌晥頄堨潓鞚� 鞎岆Μ氅�, 齑� 鞁滉皜齑濎暋鞚� $1,273,070鞛呺媹雼�. 鞁犼碃靹滌棎電� 2022雲� 1鞗旊秬韯� 2023雲� 5鞗旉箤歆� 須岇偓 欤检嫕鞝滊弰 頃橃棎 靾橂牴頃� 9臧� 氤勲弰 韸鸽灉旃橃潣 旆摑鞚检瀽鞕� 靾橂焿鞚� 旮办灛霅橃柎 鞛堨溂氅�, 旆摑響滌棎電� 齑� 8,820欤�臧� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 霕愴暅 歆�雮� 3臧滌洈臧勳潣 斓滉芳 鞛レ櫢 毵る弰 雮挫棴鞚� 氤搓碃頄堧姅雿�, 2025-06-11鞐� 99,172欤�, 2025-06-10鞐� 38,300欤�, 2025-06-03鞐� 1,642欤�, 2025-05-14鞐� 1,236欤�臧� 毵る弰霅橃柎 齑� 齑濎垬鞚奠澊 $12,853,585鞛呺媹雼�. 鞁犼碃鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 鞎呾灛 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
La d茅claration d'initi茅 d'Insmed, Inc. sur le formulaire 144 signale une proposition de vente de 10 000 actions ordinaires via Merrill Lynch sur le Nasdaq, pour une valeur marchande globale de 1 273 070 $. La d茅claration indique les dates et montants d'acquisition pour 9 tranches distinctes re莽ues dans le cadre du plan d'actions de la soci茅t茅 entre janvier 2022 et mai 2023, totalisant 8 820 actions figurant dans le tableau des acquisitions. Le d茅clarant a 茅galement signal茅 des ventes r茅centes en bourse au cours des trois derniers mois : 99 172 actions le 11/06/2025, 38 300 le 10/06/2025, 1 642 le 03/06/2025 et 1 236 le 14/05/2025, g茅n茅rant des produits bruts de 12 853 585 $. Le d茅clarant certifie l'absence d'informations d茅favorables mat茅rielles non divulgu茅es.
Die Insider-Mitteilung von Insmed, Inc. auf Formular 144 zeigt einen geplanten Verkauf von 10.000 Stammaktien 眉ber Merrill Lynch an der Nasdaq mit einem Gesamtmarktwert von $1.273.070 an. Die Einreichung listet die Erwerbsdaten und -mengen f眉r 9 einzelne Tranchen auf, die zwischen Januar 2022 und Mai 2023 im Rahmen des Aktienplans des Unternehmens erhalten wurden, insgesamt 8.820 Aktien in der Erwerbstabelle. Der Einreicher meldete au脽erdem j眉ngste Verk盲ufe am offenen Markt in den letzten drei Monaten: 99.172 Aktien am 11.06.2025, 38.300 am 10.06.2025, 1.642 am 03.06.2025 und 1.236 am 14.05.2025, was Bruttoerl枚se von $12.853.585 ergab. Der Einreicher best盲tigt, dass keine nicht offengelegten, wesentlichen negativen Informationen vorliegen.
- None.
- Insider sales disclosed: 140,350 shares sold in past three months for aggregate gross proceeds of $12,853,585.
- Proposed immediate sale: 10,000 shares valued at $1,273,070 to be executed via Merrill Lynch on 08/14/2025.
Insights
TL;DR Routine executive/private-holder sales reported; proposed 10,000-share sale follows multiple recent dispositions totaling ~140,350 shares and $12.85M proceeds.
The Form 144 details a planned brokered sale of 10,000 Insmed common shares valued at $1.27M and discloses prior open-market sales of 140,350 shares in the past three months generating roughly $12.85M. Acquisitions listed were primarily stock-plan issuances from 2022鈥�2023. For investors this is a disclosure of insider liquidity rather than new company operational information; it does not, by itself, change fundamentals. The size of recent sales relative to the ~211.37M shares outstanding is small (<0.1%), indicating limited direct supply pressure on the float from these transactions.
TL;DR The filing is a standard compliance disclosure showing insider sales under Rule 144 with a certification of no undisclosed material information.
The document lists stock-plan acquisitions and subsequent open-market dispositions and a planned sale through Merrill Lynch. The signer affirms no material nonpublic information exists. From a governance perspective, timely filing of Form 144 is appropriate and indicates transparency about insider liquidity. The filing does not indicate any departures, restrictions, or trading-plan dates that would suggest atypical governance concerns.
La comunicazione Insider di Insmed, Inc. su Form 144 segnala una proposta di vendita di 10.000 azioni ordinarie tramite Merrill Lynch sul Nasdaq, per un valore di mercato complessivo di $1.273.070. La dichiarazione indica le date e le quantit脿 di acquisizione per 9 tranche distinte ricevute nell鈥檃mbito del piano azionario aziendale tra gennaio 2022 e maggio 2023, per un totale di 8.820 azioni riportate nella tabella delle acquisizioni. Il dichiarante ha inoltre comunicato vendite recenti sul mercato aperto negli ultimi tre mesi: 99.172 azioni il 11/06/2025, 38.300 azioni il 10/06/2025, 1.642 il 03/06/2025 e 1.236 il 14/05/2025, con proventi lordi di $12.853.585. Il dichiarante certifica l鈥檃ssenza di informazioni materiali negative non divulgate.
La presentaci贸n de insider de Insmed, Inc. en el Formulario 144 notifica una propuesta de venta de 10.000 acciones ordinarias a trav茅s de Merrill Lynch en Nasdaq, con un valor de mercado agregado de $1.273.070. La notificaci贸n detalla las fechas y cantidades de adquisici贸n de 9 tramos distintos recibidos bajo el plan de acciones de la compa帽铆a entre enero de 2022 y mayo de 2023, sumando 8.820 acciones en la tabla de adquisiciones. El declarante tambi茅n inform贸 ventas recientes en mercado abierto durante los 煤ltimos tres meses: 99.172 acciones el 11/06/2025, 38.300 el 10/06/2025, 1.642 el 03/06/2025 y 1.236 el 14/05/2025, generando unos ingresos brutos de $12.853.585. El declarante certifica que no hay informaci贸n adversa material no divulgada.
Insmed, Inc.鞚� 雮措秬鞛� 鞁犼碃靹�(Form 144)電� Merrill Lynch毳� 韱淀暣 雮橃姢雼レ棎靹� 10,000 氤错喌欤� 毵り皝鞚� 鞝滌晥頄堨潓鞚� 鞎岆Μ氅�, 齑� 鞁滉皜齑濎暋鞚� $1,273,070鞛呺媹雼�. 鞁犼碃靹滌棎電� 2022雲� 1鞗旊秬韯� 2023雲� 5鞗旉箤歆� 須岇偓 欤检嫕鞝滊弰 頃橃棎 靾橂牴頃� 9臧� 氤勲弰 韸鸽灉旃橃潣 旆摑鞚检瀽鞕� 靾橂焿鞚� 旮办灛霅橃柎 鞛堨溂氅�, 旆摑響滌棎電� 齑� 8,820欤�臧� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 霕愴暅 歆�雮� 3臧滌洈臧勳潣 斓滉芳 鞛レ櫢 毵る弰 雮挫棴鞚� 氤搓碃頄堧姅雿�, 2025-06-11鞐� 99,172欤�, 2025-06-10鞐� 38,300欤�, 2025-06-03鞐� 1,642欤�, 2025-05-14鞐� 1,236欤�臧� 毵る弰霅橃柎 齑� 齑濎垬鞚奠澊 $12,853,585鞛呺媹雼�. 鞁犼碃鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 鞎呾灛 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�.
La d茅claration d'initi茅 d'Insmed, Inc. sur le formulaire 144 signale une proposition de vente de 10 000 actions ordinaires via Merrill Lynch sur le Nasdaq, pour une valeur marchande globale de 1 273 070 $. La d茅claration indique les dates et montants d'acquisition pour 9 tranches distinctes re莽ues dans le cadre du plan d'actions de la soci茅t茅 entre janvier 2022 et mai 2023, totalisant 8 820 actions figurant dans le tableau des acquisitions. Le d茅clarant a 茅galement signal茅 des ventes r茅centes en bourse au cours des trois derniers mois : 99 172 actions le 11/06/2025, 38 300 le 10/06/2025, 1 642 le 03/06/2025 et 1 236 le 14/05/2025, g茅n茅rant des produits bruts de 12 853 585 $. Le d茅clarant certifie l'absence d'informations d茅favorables mat茅rielles non divulgu茅es.
Die Insider-Mitteilung von Insmed, Inc. auf Formular 144 zeigt einen geplanten Verkauf von 10.000 Stammaktien 眉ber Merrill Lynch an der Nasdaq mit einem Gesamtmarktwert von $1.273.070 an. Die Einreichung listet die Erwerbsdaten und -mengen f眉r 9 einzelne Tranchen auf, die zwischen Januar 2022 und Mai 2023 im Rahmen des Aktienplans des Unternehmens erhalten wurden, insgesamt 8.820 Aktien in der Erwerbstabelle. Der Einreicher meldete au脽erdem j眉ngste Verk盲ufe am offenen Markt in den letzten drei Monaten: 99.172 Aktien am 11.06.2025, 38.300 am 10.06.2025, 1.642 am 03.06.2025 und 1.236 am 14.05.2025, was Bruttoerl枚se von $12.853.585 ergab. Der Einreicher best盲tigt, dass keine nicht offengelegten, wesentlichen negativen Informationen vorliegen.
FAQ
What did Insmed (INSM) disclose in this Form 144?
Who is the broker handling the proposed sale for INSM?
How many Insmed shares are outstanding according to the filing?
How much did the recent insider sales generate in gross proceeds?
What acquisition source is listed for the shares being sold?
